Mo1961 Embelin Suppresses Colitis-Associated Tumorigenesis by Inhibition IL-6/ STAT3 Signaling

Dai Yun,Teng Guigen,Wang Weihong,Qiao Liang,Zhang Rongxin

DOI: https://doi.org/10.1016/s0016-5085(13)62613-x

IF: 29.4

2013-01-01

Gastroenterology

Abstract:years was followed for 40 years.Only costs associated with surveillance from payers' perspective were considered.The analysis was conducted for three risk-level populations: (1) Average-risk patients with no pre-operative colonic neoplasia; (2) Above-average-risk patients (dysplasia of the colon as the indication for colectomy); (3) High-risk patients (cancer of the colon as the indication for colectomy).RESULTS: For the average-risk patients the incremental cost-effectiveness ratios (ICER) for no surveillance vs. surveillance every 1, 3 and 5 years were $69,105, $41,116 and $36,521 per life year gained, respectively.For the above-average-risk population the ICER for no surveillance vs. surveillance every 1, 3 and 5 years were $14,812, $8,204 and $7,075 per life year gained, respectively.For the highrisk population, the ICER for no surveillance vs. surveillance every 1, 3 and, 5 years were $3,345, $2,062 and $1,989 per life year gained, respectively.For the high risk patients, the added life years gained between surveillance every year compared to every 3 years was 1.1 years and the ICER of surveillance every year compared to every 3 years was $5,076.Sensitivity analysis revealed robust results.The Table summarizes the results.CONCLUSION: For the average-risk population surveillance pouch endoscopy every 5 years is cost-effective.For the above-average-risk or high-risk patients, surveillance every year is cost effective.